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Background: Evidence concerning the importance of glucose lowering in the prevention of cardiovascular (CV)
outcomes remains controversial. Given the multi-faceted pathogenesis of atherosclerosis in diabetes, it is likely that
any intervention to mitigate this risk must address CV risk factors beyond glycemia alone. The SGLT-2 inhibitor
empagliflozin improves glucose control, body weight and blood pressure when used as monotherapy or add-on to
other antihyperglycemic agents in patients with type 2 diabetes. The aim of the ongoing EMPA-REG OUTCOME™
trial is to determine the long-term CV safety of empagliflozin, as well as investigating potential benefits on
macro-/microvascular outcomes.
Methods: Patients who were drug-naïve (HbA1c ≥7.0% and ≤9.0%), or on background glucose-lowering therapy
(HbA1c ≥7.0% and ≤10.0%), and were at high risk of CV events, were randomized (1:1:1) and treated with empagliflozin
10 mg, empagliflozin 25 mg, or placebo (double blind, double dummy) superimposed upon the standard of care. The
primary outcome is time to first occurrence of CV death, non-fatal myocardial infarction, or non-fatal stroke. CV events
will be prospectively adjudicated by an independent Clinical Events Committee. The trial will continue until ≥691
confirmed primary outcome events have occurred, providing a power of 90% to yield an upper limit of the adjusted
95% CI for a hazard ratio of <1.3 with a one-sided α of 0.025, assuming equal risks between placebo and empagliflozin
(both doses pooled). Hierarchical testing for superiority will follow for the primary outcome and key secondary
outcomes (time to first occurrence of CV death, non-fatal myocardial infarction, non-fatal stroke or hospitalization
for unstable angina pectoris) where non-inferiority is achieved.
Results: Between Sept 2010 and April 2013, 592 clinical sites randomized and treated 7034 patients (41% from
Europe, 20% from North America, and 19% from Asia). At baseline, the mean age was 63 ± 9 years, BMI 30.6 ±
5.3 kg/m2, HbA1c 8.1 ± 0.8%, and eGFR 74 ± 21 ml/min/1.73 m2. The study is expected to report in 2015.
Discussion: EMPA-REG OUTCOME™ will determine the CV safety of empagliflozin in a cohort of patients with type
2 diabetes and high CV risk, with the potential to show cardioprotection.
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Type 2 diabetes mellitus (T2DM) is frequently associated
with comorbidities that exacerbate cardiovascular (CV)
risk, such as obesity and hypertension [1]. The risk of CV
disease is increased approximately two to four-fold in
adults with diabetes even after adjustment for conven-
tional risk factors (age, sex, smoking status, body mass
index [BMI], systolic blood pressure [BP], and lipids)
[2]. Recommended strategies for reducing CV risk in
patients with T2DM include glucose management, lipid
lowering, BP control, smoking cessation, and weight loss
[1]. Improved glycemic control has been associated with
a reduction in microvascular events [3] and there is a
clear association between microvascular complications
such as albuminuria and an increased risk of CV events
in patients with T2DM [4]. However, the impact of re-
ducing blood glucose, and the potential benefit of spe-
cific glucose-lowering agents, on CV events in patients
with T2DM remains unclear and highly controversial
[5,6]. Moreover, treatment must likely occur over a sub-
stantial duration of time, since macrovascular outcome
events are known to be late complications of a progres-
sive multifaceted pathogenic process that spans decades
[7,8]. Lately, regulatory authorities have issued guidance
for evaluating the long-term CV safety of new anti-
diabetes agents to ensure that CV safety is demonstrated
with reasonable assurance [9,10]. These mandated trials
provide an opportunity to potentially demonstrate CV as
well as microvascular benefits of new anti-diabetes drugs.
Sodium glucose cotransporter 2 (SGLT2) inhibitors are
a new class of antidiabetes agents that reduce hypergly-
cemia in patients with T2DM by reducing renal glucose
reabsorption and thus increasing urinary glucose excretion
(UGE) [11]. Empagliflozin is a potent and selective inhibi-
tor of SGLT2 [12]. In placebo-controlled phase III trials in
patients with T2DM, empagliflozin used as monotherapy
or add-on therapy improved hemoglobin A1c (HbA1c)
approximately 0.7-1.0% -point (depending on baseline
HbA1c and renal function) with a low risk of hypoglycemia,
reduced body weight and BP, without increases in heart
rate, and had small effects on plasma lipids (increase in
HDL-cholesterol, increase in LDL-cholesterol, no change in
LDL/HDL cholesterol ratio) [13-17]. In addition, empagli-
flozin has been shown to improve arterial stiffness and re-
duce glomerular hyperfiltration in patients with type 1
diabetes mellitus (T1DM) [18,19]. Moreover, SGLT2 in-
hibitors have also been reported to reduce other CV risk
markers such as visceral fat mass [20,21] and protein-
uria [22]. Based on these pleiotropic effects on CV risk
factors, we hypothesized that empagliflozin may reduce
CV risk in patients with T2DM.
The EMPA-REG OUTCOME™ trial was designed to
determine the long-term CV safety of empagliflozin in
patients with T2DM and to investigate its potentialcardioprotective effects, as well as impact on micro-
vascular outcomes, in a dedicated study that complied
with current regulatory requirements.
Methods
The EMPA-REG OUTCOME™ trial (clinicaltrials.gov
identifier: NCT01131676) is an ongoing, multicenter, ran-
domized, double-blind, placebo-controlled trial. It was de-
signed to assess the effect of empagliflozin (10 mg or
25 mg once daily) compared with placebo, in addition
to standard of care, on CV events in adults with T2DM
at high risk of CV events and with less than optimized
glycemic control.
The study protocol was approved by the respective In-
stitutional Review Boards, Independent Ethics Commit-
tees and Competent Authorities according to national
and international regulations.
Trial population
Our goal was to recruit 7000 participants across 42
countries. Patients aged ≥18 years (≥20 years in Japan
and also ≤65 years in India) with T2DM who were drug-
naïve (no anti-diabetes agents for ≥12 weeks prior to
randomization) with HbA1c ≥7.0% and ≤9.0% or taking
any background anti-diabetes therapy (except pioglita-
zone in Japan) with HbA1c ≥7.0% and ≤10.0% despite
diet and exercise counseling and who were at high risk
of CV events were eligible for inclusion. The main inclu-
sion criteria are provided in detail in Table 1. The dose
of background glucose-lowering therapy was required to
be unchanged for ≥12 weeks prior to randomization or,
in the case of insulin, unchanged by >10% from the dose
at randomization in the previous 12 weeks. Subjects
were required to have a BMI ≤45 kg/m2 at baseline.
Detailed inclusion and exclusion criteria are listed in
Additional file 1.
Study design
Eligible patients underwent a 2-week, open-label, pla-
cebo run-in period (Figure 1) during which background
glucose-lowering therapy was continued unchanged. The
purpose of the run-in period was to evaluate partici-
pants’ willingness to adhere to the long-term treatment
and follow-up planned in the trial. Following the placebo
run-in, patients still meeting the inclusion/exclusion criteria
were randomized (1:1:1) to receive empagliflozin 10 mg,
empagliflozin 25 mg, or placebo once daily in addition to
their background therapy. Background glucose-lowering
therapy was to remain unchanged for the first 12 weeks
after randomization if possible, although rescue therapy
could be initiated (details in Additional file 2). After this
period, therapy could be adjusted to achieve desired gly-
cemic control at the investigator’s discretion to achieve best
standard of care according to local guidelines. Investigators
Table 1 Key inclusion criteria
Insufficient glycemic control High risk of cardiovascular events (≥1 of the following)
• Drug-naive subjects: HbA1c ≥7.0% and ≤9.0% at
screening
• History of myocardial infarction >2 months prior to informed consent
• Evidence of multi-vessel CAD i.e. in ≥ 2 major coronary arteries or the left main coronary artery,
documented by any of the following:
• Subjects on background therapy: HbA1c ≥7.0%
and ≤10.0% at screening
– Presence of significant stenosis: ≥50% luminal narrowing during angiography (coronary or
multi-slice computed tomography)
– Previous revascularization (percutaneous transluminal coronary angioplasty ± stent or coronary
artery bypass graft >2 months prior to consent
– The combination of revascularization in one major coronary artery and significant stenosis
(≥50% luminal narrowing) in another major coronary artery
• Evidence of single-vessel CAD, ≥50% luminal narrowing during angiography (coronary or
multi-slice computed tomography) not subsequently successfully revascularized, with at least 1
of the following:
– A positive non-invasive stress test for ischemia
– Hospital discharge for unstable angina ≤12 months prior to consent
• Unstable angina >2 months prior to consent with evidence of single- or multi-vessel CAD
• History of stroke (ischemic or hemorrhagic) >2 months prior to consent
• Occlusive peripheral artery disease documented by any of the following:
– Limb angioplasty, stenting, or bypass surgery
– Limb or foot amputation due to circulatory insufficiency
– Evidence of significant peripheral artery stenosis (>50% on angiography, or >50% or
hemodynamically significant via non-invasive methods ) in 1 limb
– Ankle brachial index <0.9 in ≥1 ankle
CAD, coronary artery disease.
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Randomization and follow-up
Randomization was undertaken using a computer-
generated random sequence and an interactive voice and
web response system. Patients were stratified by HbA1c at
screening (<8.5%, ≥8.5%), BMI at randomization (<30 kg/
m2, ≥30 kg/m2), region (North America [plus Australia
and New Zealand], Latin America, Europe, Africa, Asia),Figure 1 Study design.and renal function (eGFR using the Modification of Diet
in Renal Disease [MDRD] equation) at screening (Chronic
Kidney Disease [CKD] stage 1: ≥90 ml/min/1.73 m2; CKD
stage 2: 60–89 ml/min/1.73 m2; CKD stage 3: 30–59 ml/
min/1.73 m2). Patients are instructed to attend the clinic
at pre-specified times over the duration of the study includ-
ing a follow-up visit 30 days after the end of the treatment
period (Figure 1). Patients who prematurely discontinue
study medication are asked to attend all visits as originally
planned.
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The primary outcome of the study is time to first occur-
rence of CV death, non-fatal myocardial infarction (MI,
excluding silent MI), or non-fatal stroke i.e., 3-point
major adverse cardiovascular events (3P-MACE). The key
secondary outcome expands the primary composite out-
come to include time to first occurrence of hospitalization
for unstable angina (4P-MACE). Further CV outcomes
are the individual components of the 4P-MACE, as well
as individual occurrence of and time to silent MI, heart
failure requiring hospitalization, all-cause mortality, tran-
sient ischemic attack (TIA) and coronary revascularization
procedures. All CV outcome events and deaths are being
prospectively adjudicated by the Clinical Events Commit-
tee (one for cardiac events and one for neurological
events), as recommended in FDA guidelines (FDA [9]).
Definitions of the major clinical outcomes are presented
in Additional file 3 and a non-exhaustive list of further
CV outcomes (secondary, tertiary and exploratory) in
Additional file 4.
Additional secondary outcomes include the occurrence
of and time to new onset albuminuria (urinary albumin:
creatinine ratio ≥30 mg/g) and new onset of macroalbu-
minuria (urinary albumin:creatinine ratio ≥300 mg/g).
Other outcomes include the occurrence of and time to a
composite microvascular outcome comprising the initi-
ation of laser therapy for retinopathy, vitreous hemorrhage,
diabetes-related blindness, and new or worsening nephrop-
athy (new onset macroalbuminuria [albumin:creatinine
ratio ≥300 mg/g]; doubling of serum creatinine accom-
panied by eGFR ≤45 mL/min/1.73 m2; initiation of renal
replacement therapy; or death due to renal disease) as well
as the individual components of this composite.
The short (12 weeks), medium (52 weeks), and long-
term (annually, at end of study, and at follow-up) effects
of the two doses of empagliflozin on HbA1c, fasting plasma
glucose (FPG), body weight, waist circumference, and BP
will be assessed, as well as the proportion of patients who
meet the composite outcome of HbA1c reduction ≥0.5%,
systolic BP reduction >3 mmHg, and body weight re-
duction >2%.
The prognostic impact of, and the modulating poten-
tial of empagliflozin on, the renal biomarker cystatin C
and the CV biomarkers high-sensitivity C-reactive pro-
tein and high sensitivity troponin T will be assessed in
sub-studies, as will potential associations between gen-
etic variations and drug response.
Safety will be assessed based on adverse events (AEs)
reported throughout the study and up to 7 days after the
last dose of study medication (coded using the Medical
Dictionary for Drug Regulatory Activities [MedDRA]),
clinical laboratory tests, vital signs, 12-lead electrocar-
diogram (ECG), physical examination, and the use of
rescue medication. Pre-specified AEs of special interest(AESI) include confirmed hypoglycemic adverse events
(plasma glucose ≤70 mg/dL (3.9 mmol/L) and/or requir-
ing assistance), those reflecting volume depletion, bone
fracture, hepatic events, malignancies, urinary tract infec-
tion (UTI), and genital infection. Events may be defined
by either abnormal laboratory values and/or relevant ad-
verse events identified using prospectively defined search
categories or both. For qualifying events, relevant source
documentation will be requested including lab values,
histological analysis, results of ultrasound, CT, MRI, scin-
tigraphy, hospital discharge letters, and medical reports
from other physicians. All evaluations will be performed
in a blinded fashion.
A list of efficacy and safety outcomes is presented in
Additional file 4.Study oversight and organization
The trial was jointly designed by employees of Boeh-
ringer Ingelheim (BI) and the academic investigators
who were members of the Steering Committee. The
Steering Committee, which was led by the academic
investigators and included members who were em-
ployees of the sponsor, supervised the trial design and
operation. The independent data and safety monitoring
committee (DMC) reviews interim safety data every
90 days or on an ad hoc basis on request. A list of com-
mittees involved in the trial conduct is presented in
Additional file 5.Statistical considerations
Sample size and power calculations
The primary hypothesis aims to show non-inferiority on
3P-MACE for empagliflozin versus placebo based on a
non-inferiority margin of < 1.3 (upper limit of the ad-
justed 95% confidence interval (CI)) for the hazard ratio.
The upper limit of the adjusted 95% CI for the HR of <1.3
was based on FDA guidance for CV trials evaluating new
anti-hyperglycemic therapies for T2DM [9]. Patients who
receive either 10 mg or 25 mg of empagliflozin will be
pooled into a common treatment group for the purposes
of the primary analysis. A 4-step hierarchical testing strat-
egy will be followed: 1) non-inferiority test of the primary
outcome (3P-MACE), 2) non-inferiority test of the key
secondary outcome (4P-MACE), 3) superiority test of the
primary outcome (3P-MACE) and 4) superiority test of
the key secondary outcome (4P-MACE). A minimum of
691 confirmed primary outcome events are required to
provide 90% power with a one-sided α level of 0.025, as-
suming equal risk between the placebo and empagliflozin
groups. With a minimum of 691 events, the trial will also
have at least 80% power to detect a hazard ratio of 0.785
(corresponding to a 21.5% risk reduction in CV outcome
events) for the primary outcome.
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In order to support a CV meta-analysis of all CV events
occurring in the phase III trials involving empagliflozin,
as required for all New Drug Applications to be submit-
ted to the FDA [9], CV outcome data from the ongoing
EMPA-REG OUTCOME™ was extracted. The cut off for
the data extraction was preplanned and ~ 150 4P-MACE
were included in the project level CV meta-analysis.
This resulted in addition of a Haybittle-Peto correction
for the interim analysis (i.e., 0.0001 of the α was spent
on the data extraction for the interim analysis), and sub-
sequent reduction of the final α level to 0.0249 (in order
to maintain the experiment-wise α level of 0.025).
The need to prevent the release of any data from the
data extraction or interim analysis that could define the
effects of empagliflozin on CV outcomes was fundamen-
tal to the study design [23]. Accordingly, procedures, in-
cluding restricted access to electronic systems, were put
in place to ensure that the effect estimate remained
blinded and data review by the regulators would not re-
quire premature disclosure of the effects of empagliflozin
on CV outcome. The data extraction, interim analysis and
the following phase III CV meta-analysis were performed
by a group independent from the EMPA-REG OUT-
COME™ trial team, so that the trial’s operational team and
the academic Steering Committee remained blinded to
the results. The DMC is the sole group with access to un-
blinded results beyond the strictly firewalled “CV meta-
analysis group” of the sponsor.
Analysis plan
Three analysis populations are defined for this trial: 1) The
treated set (TS), consisting of all patients who were treated
with at least one dose of study drug, 2) The on-treatment
set (OS), consisting of patients who received the drug for at
least 30 days (cumulative) in whom events will be consid-
ered that occurred within 30 days of the off-treatment
period or until the end of the entire trial, whichever will be
earlier (patients who did not experience the primary out-
come will be censored at the end of the treatment period, if
the patient completes treatment as planned, or at the end
of the 30 day period) and 3) the Full Analysis Set (FAS),
consisting of all patients randomized, treated with at least
one dose of study drug and with a baseline HbA1c value.
The primary analysis will be based on a Cox propor-
tional hazards model with treatment (with empagliflozin
10 mg and 25 mg pooled into a single group), age, gender,
baseline BMI (<30 kg/m2, ≥30 kg/m2), baseline HbA1c
(<8.5%, ≥8.5%), baseline eGFR as well as geographical re-
gion (classified as North America, Latin America, Europe,
Africa and Asia) as factors. The same Cox proportional
hazards model as for the primary outcome will be
employed in all steps of the hierarchical testing strategy
(3P-MACE and 4P-MACE).The time to the occurrence of the primary outcome
and the key secondary outcomes event will be computed
as (event date − randomization date) +1. Patients who do
not have the event during the trial period will be cen-
sored at the individual day of trial completion. The time
to censoring will be computed as (individual day of trial
completion – randomization date) + 1. For patients who
have more than one primary outcome event during the
trial, the time to the first occurrence of the primary out-
come event will be considered for the primary analysis.
All adjudicated and confirmed events will be used for
the primary analysis.
The TS is the basis for the primary analysis and the
FAS is the basis for the intention-to-treat (ITT) analysis
for efficacy analyses. As sensitivity analyses the primary
analysis will also be performed for the OS. Secondary
analyses of the primary analysis with pooled active treat-
ment arms will be performed by comparing the active
treatments individually versus the placebo arm. Sensitiv-
ity analyses of the primary and key secondary outcomes
will be performed that include the additional factor of
naïve/experienced drug status in the Cox model. The
secondary and tertiary further cardiovascular outcomes
will be analyzed in a Cox proportional hazards model
similar to the primary analysis for the treated set. Of
note is that also other sensitivity analysis will be con-
ducted employing other statistical methods, as well as an
assessment of outcomes per individual dosages (i.e.,
empagliflozin 10 mg and empagliflozin 25 mg).
Subgroups to be considered in the analyses will be de-
fined based on, but not limited to, age, HbA1c, BMI,
weight, geographical region, race, gender, ethnicity, time
since diagnosis of T2DM, renal function, BP, eGFR,
glucose-lowering and CV prophylactic medication, CV
complications and cohort, all defined at study baseline
or screening. In addition, outcomes in patients experi-
encing severe hypoglycaemia vs those not experiencing
severe hypoglycaemia will be assessed. Further details as
to the specific categories to be employed for each sub-
group factor are provided in Additional file 6.
Patient recruitment and baseline characteristics
Recruitment into the EMPA-REG OUTCOME™ trial
began in September 2010 and was completed in April
2013. In total 11507 patients were screened and 7042
participants were randomized to receive study treat-
ment at 592 clinical sites in 42 countries. The main rea-
son for screen-failure was that the HbA1c fell outside
protocol specifications. Of those randomized, 7034 partici-
pants were treated. The baseline characteristics of treated
participants are shown in Table 2. Most came from
Europe (41%) or North-America (20%) with 19% from
Asia, 15.4% from Latin America and 4% from South-
Africa. The mean age of participants was 63 years, with
Table 2 Baseline characteristics (treated set; n = 7034)
Age (years), mean (SD) 63.1 (8.6)
≥ 75 years of age, n (%) 652 (9)
Male, n (%) 5026 (72)
Race, n (%)
White 5089 (72)
Asian 1518 (22)
Black/African American 357 (5)
Other* 70 (1)
Ethnicity, n (%)
Hispanic or Latino 1268 (18)
Smoking history, n (%) Current/Ex-smoker 930 (13)/3216 (46)
Time since diagnosis, n (%)
≤5 years 1265 (18)
>5-10 years 1754 (25)
>10 years 4015 (57)
Region, n (%)
Europe 2885 (41)
North America/Australia/New Zealand 1408 (20)
Latin America 1081 (15)
Africa 313 (4)
Asia 1347 (19)
Northeast Asia 586 (8)
South/South-East Asia 761 (11)
CV risk factors, any of the below, n (%) 6978 (99)
History of MI 3275 (47)
Single-vessel CAD 743 (11)
Multi-vessel CAD 3285(47)
CABG 1738(25)
History of stroke 1631 (23)
Peripheral occlusive arterial disease 1449 (21)
Glucose-lowering therapy at baseline, n (%)
None 128 (2)
Monotherapy 2055 (29)
Metformin (% of monotherapy) 745 (36)
Insulin (% of monotherapy) 954 (46)
Dual therapy 3188 (45)
Metformin + sulfonylurea (% of dual therapy) 1383 (43)
Metformin + insulin (% of dual therapy) 1420 (45)
Other therapies (n, %)
Acetylsalicylic acid 5990 (85)
Statins 5387 (77)
Fibrates 630 (9)
Table 2 Baseline characteristics (treated set; n = 7034)
(Continued)
Any antihypertensive therapy (n, %) 6641 (94)
Blockers of the renin-angiotensin system 5651 (80)
Beta-blockers 4537 (64)
Calcium channel blockers 2114 (30)
*American Indian/Native Alaskan/Native Hawaiian/Pacific Islander/missing.
Results (based on a pre-final version of the database of this ongoing trial) may
change slightly once trial is completed.
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72% are white. Time since diagnosis of T2DM was
≤5 years in 18% of participants and >10 years in 57%. At
baseline, mean HbA1c was 8.1% (Table 3) with 68% of par-
ticipants having HbA1c <8.5%. Only 2% of participants were
drug-naïve; 29% were receiving monotherapy, and 45%
were receiving dual therapy. Insulin was used by 36% of
participants (as monotherapy or part of dual therapy). A
history of CV complications or CV events was demon-
strated in 99% of participants and in total 47% had a history
of MI and 23% a history of stroke. Fifty-two per cent of par-
ticipants had an eGFR ≥ 60 and <90 mL/min/1.73 m2 (i.e.,
stage 2 CKD) and 26% had an eGFR ≥ 30 and <60 mL/min/
1.73 m2 (i.e., stage 3 CKD). Albuminuria (UACR ≥30 mg/g)
was present in 40% of participants. At baseline, 77% of pa-
tients were receiving a statin, 9% were receiving a fibrate,
85% were being treated with an acetylsalicylic acid agent,
and 94% were receiving any drug for BP reduction (80% on
blockers of the renin-angiotensin system).
Discussion
The EMPA-REG OUTCOME™ trial is an ongoing, ran-
domized, placebo-controlled, clinical outcomes trial pow-
ered to establish the CV safety of empagliflozin with the
potential to demonstrate cardioprotection in patients with
T2DM at high risk of CV events who are receiving stand-
ard of care.
The pragmatic inclusion of patients on any back-
ground glucose-lowering agents will enable an assess-
ment of the long-term CV effects of empagliflozin in a
representative cohort and in a setting similar to real-life
clinical practice. Of further note is that the trial will be
able to assess the impact of empagliflozin on CV risk, in
particularly vulnerable patient groups since ~ 25% pa-
tients have eGFR < 60 and ~10% were ≥75 years of age
at baseline. Further, given the diversity of background
therapy being allowed, CV outcomes according to type
of background therapy can be derived. Recruitment into
the study is complete and the baseline characteristics of
the 7034 treated participants indicate that, as planned,
they are at high risk of CV events and we anticipate that
the pre-specified number of 3P-MACE will be reached in
2015. Thus, this trial will be one of the first, if not the first,
to report final CV outcome data amongst the ongoing
Table 3 Key baseline laboratory data (treated set;
n = 7034)
HbA1c (%), mean (SD) 8.1 (0.8)
HbA1c <8.5%, n (%) 4811 (68)
Fasting plasma glucose (mmol/L), mean (SD) 8.5 (2.4)
Body mass index (kg/m2), mean (SD) 30.6 (5.3)
≥ 35 kg/m2, n (%) 1426 (20)
Weight (kg), mean (SD) 86.4 (18.9)
Waist circumference (cm), mean (SD) 105 (14)
Systolic/diastolic blood pressure (mmHg), mean (SD) 135 (17)/77 (10)
Lipids (mmol/L), mean (SD)
Total cholesterol 4.2 (1.1)
LDL-cholesterol 2.2 (0.9)
HDL-cholesterol 1.2 (0.3)
Triglycerides 1.9 (1.4)
eGFR according to MDRD (mL/min/1.73 m2), mean (SD) 74 (21)
eGFR according to MDRD (mL/min/1.73 m2), n (%)
≥90 1534 (22)
60 to <90 3671 (52)
30 to <60 1796 (26)
ACR albumin ratio (mg/g), median (Q1, Q3) 17.7 (7.1, 72.5)
ACR ratio (mg/g), n (%)
≥ 30 – 300 2011 (29)
≥ 300 771 (11)
Results (based on a pre-final version of the database of this ongoing trial) may
change slightly once trial is completed.
Zinman et al. Cardiovascular Diabetology 2014, 13:102 Page 7 of 8
http://www.cardiab.com/content/13/1/102SGLT2i CV outcome trials: DECLARE-TIMI58 (clinical-
trials.gov identifier: NCT01730534) involving dapagliflozin,
CANVAS (clinicaltrials.gov identifier: NCT01032629) in-
volving canagliflozin [24] and the ertugliflozin CV outcome
study (clinicaltrials.gov identifier: NCT01986881), which all
according to public sources will complete 2017–2020.
With 7034 patients enrolled and treated, the trial is in
keeping with the 2008 FDA guidance on evaluating the
CV risk of new therapies to treat T2DM [9] but may
also provide insights beyond CV safety, including impact
on microvascular, in particular renal outcomes, as de-
tailed above. A theoretical basis for renal protection with
SGLT2 inhibitors has been proposed, encompassing re-
duction in tubular stress as well as glucose-induced in-
flammation and fibrotic markers in the proximal tubule
in vitro and in animal models, as well as improvement
in glucose and BP control, reduction in plasma uric acid
and albuminuria, and reduction in glomerular hyperfil-
tration with improvement in glomerular capillary hyper-
tension [19,22,25-28].
Since the majority (i.e., 78%) of participants in EMPA-
REG OUTCOME™ had some degree (i.e. CKD 2 or 3) of
renal impairment at baseline, including 11% with macro-
albuminuria, this trial is also expected to provide valuableinformation on the effect of empagliflozin on renal out-
comes. Of note, renal outcomes comprise the dedicated
scope for two other SGLT2i outcome trials, i.e., the
CANVAS-R trial (clinicaltrials.gov identifier NCT01989754)
which will investigate the effects of canagliflozin on pro-
gression of albuminuria in 5700 patients with T2DM
and the CREDENCE trial (clinical trials.gov identifier
NCT02065791) which will investigate the effects of cana-
gliflozin on the incidence of end-stage kidney disease,
serum- creatinine doubling and renal and CV death in
3627 patients with T2DM and stage 2 and 3 CKD and
macroalbuminuria, estimated to report in 2017 and 2019,
respectively.
In summary, it is expected that the results of the
EMPA-REG OUTCOME™ trial will provide evidence
concerning the CV safety of empagliflozin, as well as
provide insights on the potential benefits of empagliflo-
zin on CV and microvascular outcomes. Thus the results
of the EMPA-REG OUTCOME™ trial will help to inform
clinical decision-making for patients with T2DM.
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